Search

Background: Ki‐67 is an index of proliferative activity and is an established predictive and prognostic marker in multiple malignancies. However, its prognostic relevance in multiple myeloma (MM) is unclear. We investigated the relationship between Ki‐67 expression and survival outcomes in MM in the era of novel therapies. Methods: We interrogated our database to identify patients with MM, newly diagnosed between July 1, 2013 and December 31, 2020, with Ki‐67 expression assessed by immunohistochemistry (IHC) on bone marrow biopsies. Using an established threshold of 5% we defined Ki‐67low (≤5%) and Ki‐67high (>5%) subgroups for association with progression‐free survival (PFS) and overall survival (OS). Results: Of 167 patients included: 53 (31.7%) had Ki‐67high and 114 had Ki‐67low. More patients with R‐ISS 3 had Ki‐67high (22.2% vs. 9.7%). The gain of 1q21 was overrepresented in the Ki‐67high group (28% vs. 8%). Median PFS in the Ki‐67low group was 3.1 years, and in the Ki‐67high group 1.6 years (log‐rank p <.001, HR: 1.9). Median OS was not reached in the Ki‐67low vs. 4.8 years in the Ki‐67high cohort (HR: 1.9; log‐rank test: p =.018). In the multivariable modeling, after adjusting for other risk factors, HR for Ki‐67high versus Ki‐67low was 2.4 (p <.001) for PFS and 2.1 (p =.026) for OS. Conclusions: Our results demonstrate that a high Ki‐67 index (>5%) is an independent prognostic marker associated with worse OS and PFS in newly diagnosed MM. IHC staining for Ki‐67 on bone marrow biopsies could be easily adopted as a prognostic biomarker for MM in economically constrained healthcare settings. [ABSTRACT FROM AUTHOR]

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is an exceedingly rare extra-nodal variant of diffuse large B-cell lymphoma (DLBCL) with an aggressive natural history that often manifests as red cutaneous tumour lesions on the lower extremities. Additionally, with the chemoresistant nature of PCDLBCL-LT and the relatively poor prognosis, many patients experience disease relapse and thus, novel treatment paradigms are needed for salvage therapy. PET/CT 13 months after starting therapy shows continued CR, and the patient remains in remission clinically at 20 months. After four cycles of therapy, an interim PET/CT scan demonstrated a CR with no hypermetabolic uptake to indicate active, recurrent, or metastatic disease. [Extracted from the article]